TEI Biosciences was founded by Dr. Eugene Bell, Professor Emeritus of Biology at MIT, and began operations upon receipt of an award from NIST. The company s history and expertise in regenerative medicine has led to the development of some of the leading patented platform technology, as well as a family of engineered devices called EBM. EBM is processed in a patented method that results in a strong, highly biocompatible collagen scaffold, approved by the FDA for use as a surgical mesh for a broad spectrum of tissue repair applications. The EBM products include TissueMend, Durepair, Xenform, PriMatrix, and SurgiMend. TissueMend was launched in the United States during August 2003, and is marketed by Stryker Orthopaedics. Durepair was launched in Europe during April 2004, and is marketed by Medtronic Neurosurgery. TEI also has an agreement with another medical device company for the global marketing of Xenform.
Partial Data by Infogroup (c) 2024. All rights reserved.